Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lyndra Raises $55 Million for Long-Acting Drug Delivery; HOPU Participates

publication date: Jan 30, 2019

Lyndra Therapeutics of Boston raised $55 million in a Series B financing to support its ultra-long-release drug delivery technology. The round was led by Polaris Partners, an early backer of Lyndra, and it was joined by several new investors including HOPU Investments, a Beijing private equity firm, and the Gates Foundation, plus Gilead Sciences, Invus and Orient Life. Lyndra plans to file an IND for a Phase II trial of a long-acting schizophrenia pill this year. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital